Abbott's TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lip...(ved TRILIPIX in combination with rosuvas...),Health

Date:6/8/2009

ved TRILIPIX in combination with rosuvastatin to those who received the corresponding dose of rosuvastatin alone, the pre-determined monotherapy. The ADA lipid targets included LDL less than 100 mg/dL, triglycerides less than 150 mg/dL and HDL greater than 40 mg/dL for men and greater than 50 mg/dL for women.

About the Study Results

More patients simultaneously achieved all three ADA lipid targets for HDL, triglycerides and LDL when receiving TRILIPIX in combination with rosuvastatin 10 mg (28.3 percent vs. 8.3 percent; p=0.012) or 20 mg (19.1 percent vs. 5.9 percent; p= 0.045) compared to rosuvastatin 10 mg or 20 mg alone, respectively. Additionally, TRILIPIX in combination with rosuvastatin 5 mg resulted in 21.7 percent of patients achieving all three ADA lipid targets simultaneously compared to 12.1 percent of patients receiving rosuvastatin 5 mg alone (p=0.137). TRILIPIX monotherapy resulted in 4.3 percent of patients obtaining simultaneous achievement of these goals.

"The clinical program continues to generate important data supporting the use of TRILIPIX in combination with rosuvastatin therapy in high risk patient populations," said Eugene Sun, M.D., vice president, Global Pharmaceutical Clinical Development, Abbott.

TRILIPIX Clinical Development Program

The TRILIPIX clinical program studied 3,458 patients with mixed dyslipidemia in four 12-week controlled studies where patients received TRILIPIX alone, TRILIPIX in combination with one of the three most commonly prescribed statins (atorvastatin, simvastatin or rosuvastatin) or statin alone. The clinical program also included a 52-week, long-term, open-label extension study.

Important Safety Information About TRILIPIX

TRILIPIX should not be taken by people with liver, gallbladder, or severe kidney disease, nursing mothers, or those allergic to any product ingredient. Unexplained muscle pain,
'/>"/>

SOURCE Abbott Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)
2. (Multimedia Version): Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management
3. Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management
4. QLT announces positive results from the evaluation of Visudyne(R) combination therapy
5. 2-drug combination appears safe and active in metastatic kidney cancer
6. New treatment combination proves safe for head and neck cancer patients
7. Study shows drug combination improves outcome for advanced non-small cell lung cancer
8. Chemotherapy combination outcomes differ for aged, younger colon cancer patients
9. Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
10. Transplant Surgery and Identity: A Discussion Among Pioneers with Unusual Combinations of Interests, Skills and Talents
11. Mayo Clinic Researchers Say Triple Drug Combination is Promising Option to Treat Metastatic HER2+ Breast Cancer